Signet Therapeutics

Signet Therapeutics is a clinical-stage biotech company pioneering the development of first-in-class targeted cancer therapies using organoids and AI. Our lead program, SIGX1094, has entered Phase I clinical trials as a potential first-in-class targeted therapy for diffuse gastric cancer, a highly aggressive cancer with no approved targeted treatments. SIGX1094 has received FDA Orphan Drug Designation and Fast Track Designation. It is also the world's first drug candidate developed by organoid and AI. In addition to advancing our own pipeline, our organoid platform is available for external collaborations, providing innovative preclinical drug discovery and development services to biotech and pharmaceutical partners. Driven by a vision to address urgent unmet medical needs, we are committed to transforming cancer treatment through cutting-edge science. Our team of experts embraces rigorous research, fearless innovation, and a relentless pursuit of excellence to bring new hope to cancer patients worldwide. Contact us: contact@signettx.com Join us: hr@signettx.com